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AbstrAct
Objectives Aberrant PI3K/AKT/mTOR activation is 
common in gynaecological malignancies. However, 
predictive biomarkers of response to PI3K pathway 
inhibitors (PAMi) have yet to be identified.
Methods We analysed the outcomes of patients with 
advanced gynaecological cancer with available genomic 
data, treated with PAMi as single agents or in combination 
in phase I clinical trials. Clinical relevance of the PIK3CA 
mutant allele fraction (MAF) was investigated. MAF of each 
variant was normalised for tumour purity in the sample 
(adjMAFs) to infer clonality of PIK3CA mutations, defined 
as clonal (≥0.4) or subclonal (<0.4).
Results A total of 50 patients with gynaecological 
cancer (24 ovarian; 15 endometrial; 11 cervical) with 
available targeted mutation profiling were selected. PAMi 
therapy was matched to PIK3CA/PTEN mutation in 30 
patients (60%). The overall response rate, median time to 
progression (mTTP) and clinical benefit rate (CBR) of the 
entire population were 10% (N=5), 3.57 months (2.57–4.4) 
and 40% (N=18), respectively. Genotype-matched therapy 
did not lead to a favourable CBR (OR 0.91, p=1 (0.2–3.7)) 
or mTTP (3.57 months (2.6–4.4) vs 3.73 months (1.9–
13.2); HR 1.41; p=0.29). We did not detect differences 
in mTTP according to therapy or PIK3CA codon mutation 
(HR 1.71, p=0.24). Overall, 41% of patients had a TTP 
ratio (TTP PAMi/TTP on immediately prior or subsequent 
palliative chemotherapy) ≥1.3, without statistically 
significant differences according to tumour type (p=0.39), 
molecular alteration status (p=0.13) or therapy (p=0.54). 
In univariate analysis, genotype-matched therapy in 
patients with PIK3CA clonal events was associated with 
improved mTTP (HR 3.6; p=0.03).
Conclusions Our study demonstrates that patients with 
advanced gynaecological cancer, refractory to standard 
therapies, achieved meaningful clinical benefit from PAMi. 
The impact of PI3KCA clonality on response to selected 
PAMi in patients with gynaecological cancer deserves 
further investigation.
IntROduCtIOn
The PI3K pathway is often dysregulated in 
gynaecological malignancies,1–4 and it has 
been assessed as a target for novel ther-
apeutic strategies over the last decade. 
However, despite preliminary evidence 
of meaningful clinical benefit with PI3K/
AKT/mTOR inhibitors (PAMi), particularly 
among patients with endometrial and ovarian 
cancer,5 our current understanding of 
molecular predictors of response is limited. 
Research efforts are ongoing to further 
elucidate the mechanisms of response and 
resistance to these drugs. Preclinical studies 
suggest that activating oncogenic mutations 
in PIK3CA and/or loss of PTEN expression 
predict response to PAMi in gynaecological 
malignancies.6–8 Conversely, mutations in 
mitogen-activated protein kinase (MAPK) 
Key questions
What is already known about this subject?
 ► The PI3K pathway is often dysregulated in gynaeco-
logical malignancies.
 ► The current understanding of molecular predictors 
of response to PI3K/AKT/mTOR inhibitors is limited.
 ► Clonal evolution of PIK3CA mutations has not been 
investigated as a predictive biomarker of response 
to PI3K/AKT/mTOR inhibitors in gynaecological 
malignancies.
What does this study add?
 ► Our study is one of the largest series reported of gy-
naecological tumours that have been prospectively 
analysed with next-generation sequencing through 
an institutional screening programme and treated 
with PI3K/AKT/mTOR inhibitors.
 ► Patients with advanced gynaecological cancer re-
fractory to standard therapies achieved meaningful 
clinical benefit from PI3K/AKT/mTOR inhibitors.
 ► PI3KCA clonality impacted on response to selected 
PI3K/AKT/mTOR inhibitors in patients with gynaeco-
logical cancer.
How might this impact on clinical practice?
 ► Despite existing barriers that limit access to geno-
type-matched therapies for gynaecological cancers, 
and the complexity of PI3K pathway inhibition, our 
data suggest that estimating PIK3CA mutation clon-
ality may be important to guide the selection of PI3K/
AKT/mTOR inhibitors in patients with advanced gy-
naecological cancer.
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pathway, such as KRAS, NRAS and BRAF, might be asso-
ciated with innate resistance to PAMi.6–8 The integration 
of next-generation sequencing (NGS) platforms to both 
prescreening programmes and clinical trials has revealed 
a wide spectrum of clinically relevant genomic alterations 
in the PI3K and MAPK pathways, improving our under-
standing of the genomic drivers of gynaecological malig-
nancies.9 New insights in solid tumours are providing a 
deeper understanding of the PI3K pathway and its targ-
etability. Development of second-generation drugs, such 
as isotype-specific PI3K inhibitors, has been associated 
with improved outcomes in patients with non-colorectal 
PI3KCA-mutated cancer treated in early-phase clinical 
trials.10 Clonal evolution of PIK3CA mutations has also 
been investigated as a predictive biomarker of response 
to PAMi in patients with breast11 or colorectal12 cancer, 
but the results were not conclusive.
Mutant allele fractions (MAFs), defined as the number 
of mutant reads divided by the total number of reads 
(coverage) at a specific genomic position, may influence 
prognosis and response to targeted therapies, including 
EGFR kinase inhibitors in EGFR-mutated lung cancer.12–16 
Although MAFs of driver genes are more likely to be clonal 
compared with MAFs of those that are not considered 
putative drivers, studies have shown that genes involved 
in the PI3K pathway, such as PIK3CA, have a higher 
proportion of subclonal events than those in the MAPK 
pathway.17 Due to the strong influence of both tumour 
purity (fraction of neoplastic cells in the sample) and 
ploidy (either copy number gains or losses of wild-type/
mutant alleles) on MAFs, the ‘adjusted MAF’ (adjMAF) 
for driver genes has been used to describe a clonal or 
subclonal distribution in individual tumour samples.12
Here, we investigated the feasibility and utility of 
conducting PI3K and MAPK pathway genomic charac-
terisation in a cohort of patients with advanced gynae-
cological cancer enrolled on a prospective genomic 
profiling protocol at the Vall d’Hebron Institute of 
Oncology (VHIO). As an exploratory objective, we anal-
ysed the association of clinical and molecular markers, 
such as PIK3CA-mutated variants and clonality, with the 
magnitude of response and clinical benefit with geno-
type-matched PAMi in early phase I clinical trials.
MateRIals and MetHOds
Patient population
Our study cohort included patients with advanced gynae-
cological malignancies who had experienced disease 
progression with standard regimens and provided consent 
for NGS at VHIO from March 2010 to November 2016 as 
part of a molecular prescreening programme (MPP) for 
early drug development trials. Patients who were oppor-
tunistically enrolled onto phase I clinical trials with PAMi, 
as a single-agent or in combination with other targeted 
drugs, were included in our study cohort. We excluded 
patients who received PAMi combined with cytotoxic 
drugs. Clinical data were retrospectively extracted from 
medical records by data curators from the Oncology Data 
Science (ODysSey) group.
specimens
Archival tumour specimens were obtained from a biopsy 
or surgical resection of a primary or metastatic site of 
disease. Tumour area content from sections of forma-
lin-fixed paraffin-embedded tissue was evaluated by a 
pathologist. A minimum tumour content of 20% was 
required in order to allow subclonal somatic mutation 
detection. Tumour purity was defined as the amount of 
sample occupied by cancer cells and not by surrounding 
stromal and immune/inflammatory cells. To minimise 
variability, the quantification of neoplastic cells was 
performed by an experienced pathologist (PN) in the 
same section used for sequencing, as recently recom-
mended by other groups.18
Mutation analysis
NGS testing was performed at the VHIO Cancer 
Genomics Lab (UNE-EN ISO 15189:2013). Two molec-
ular profiling assays were used over the study period. 
Between January 2010 and May 2014, mutation detection 
and quantification was performed using a multiplex mass 
spectrometry–based technology platform (massARRAY 
Sequenom), targeting hotspot mutations across 24 onco-
genes, including frequent variants in PIK3CA, AKT1, 
KRAS, NRAS and BRAF). In June 2014, we transitioned 
to an amplicon-based NGS technology (MiSeq Illumina) 
platform assessing a total of 61 oncogenes and tumour 
suppressor genes, including frequently mutated exons of 
PIK3CA, AKT1, PTEN, KRAS, NRAS and BRAF. Average 
sequencing depth was 1000x allowing precise estimates 
for low MAFs (mutations were called at a minimum MAF 
of 3%). The calculated adjMAFs (MAF/tumour purity) 
of driver genes of interest were used to infer clonality of 
the events. A cut-off point of 0.4 was used taking the refer-
ence of the mean value of adjMAF in our population. We 
defined adjMAF ≥0.4 in PIK3CA as clonal and <0.4 as 
subclonal (online supplementary methods).
Clinical data collection and efficacy endpoints
Baseline patient and tumour characteristics, treatment 
regimen(s) and response were retrieved from medical 
records. Patients were categorised in two groups based 
on tumour mutational status: (1) PI3K-altered (PIK3CA, 
AKT1 and/or PTEN mutations) cohort that received 
PAMi (genotype-matched); and (2) PI3K non-altered 
cohort that received PAMi. Response was assessed per 
Response Evaluation Criteria in Solid Tumours (RECIST) 
V.1.1. Time to progression (TTP) was defined as the time 
interval from the start of treatment to discontinuation 
due to disease progression or death, whichever occurred 
first (patients with permanent treatment discontinuation 
for toxicity without evidence of progressive disease were 
censored at the time of the last dose). Clinical benefit rate 
(CBR) was defined as the proportion of patients achieving 
complete response, partial response or stable disease >4 
Open access
3Rodriguez-Freixinos V, et al. ESMO Open 2019;4:e000444. doi:10.1136/esmoopen-2018-000444 Rodriguez-Freixinos V, et al. ESMO Open 2019;4:e000444. doi:10.1136/esmoopen-2018-000444
months. Median TTP on palliative chemotherapy given 
immediately before or after PAMi was estimated. The 
ratio of TTP on PAMi to TTP on chemotherapy was calcu-
lated and considered clinically meaningful if ≥1.3.19
statistical analysis
A descriptive analysis of the variables included in the study 
was performed. Continuous variables were expressed as 
median and range or IQR, and categorical variables were 
expressed as absolute values and percentages. For the 
univariate analysis, Fisher’s exact test was used for cate-
gorical variables and the Mann-Whitney U test for contin-
uous variables. Survival analysis was calculated using the 
Kaplan-Meier method and log-rank test was used for 
statistical comparison. Multivariate Cox proportional-haz-
ards models were used to obtain HRs with 95% CIs. All 
tests were two-sided, and a p value <0.05 was considered 
statistically significant. The data analyses were carried out 
using R V.3.2.3 statistical software and survival package.
Results
Patient cohort
Between March 2010 and November 2016, a total of 
264 patients with gynaecological cancer had available 
results from targeted NGS, including 152 patients with 
ovarian, 75 endometrial and 37 cervical cancer. Of these, 
50 patients received PAMi treatment, regardless of PI3K 
pathway mutation status, of which 24 patients (48%) had 
ovarian cancer, 15 (30%) had endometrial and 11 (22%) 
had cervical carcinoma. Median age was 57 years (range, 
30 to 70 years). Patients had received a median of two 
prior lines of systemic treatments (range, 1–6). Patient 
characteristics are detailed in table 1.
Molecular profiling
Of the PAMi-treated cohort, 32 patients (64%) had a 
sample tested using the massARRAY Sequenom platform 
and 18 (36%) were tested with the MiSeq Illumina plat-
form. One or more somatic mutations were detected in 
39 (78%) patients. Sequencing was mostly performed on 
samples derived from primary archival tissue (n=40; 80%) 
versus metastatic specimens (n=10; 20%). The preva-
lence of oncogene mutations in our cohort is depicted in 
figure 1A. The most frequently mutated gene was PIK3CA 
(52%), followed by KRAS (24%), PTEN (12%), AKT1 
(2%) and NRAS (2%). PIK3CA mutations were detected 
in 11 (46%) of 24 patients with ovarian cancer, 6 (40%) 
of 15 patients with endometrial cancer and 9 (82%) out 
of 11 patients with cervical cancer treated with PAMi. 
Mutations in exon 9 of PIK3CA were found in 17 (34%) 
patients and 9 (18%) patients had PIK3CA exon 20 muta-
tions. The most frequent mutation was E545K (1633G>A) 
in nine (18%) patients, followed by H1047R (3140A>G) 
in eight (16%) patients and E542K (1624G>A) in four 
(8%) patients. Concomitant MAPK pathway (KRAS, 
NRAS) mutations and PIK3CA were identified in three 
(6%) patients (two with cervical cancer and one with 
endometrial cancer). NRAS mutation was detected in 
one (2%) patient and another patient had concomitant 
KRAS/NRAS mutations.
Median adjMAF of PIK3CA was 0.36 (IQR 0.25–0.49; 
range, 0.12–1.0), with 10 of 26 cases (38%) having poten-
tially subclonal events (adjMAF <0.4). We explored differ-
ences in adjMAFs of PIK3CA according to histology and 
found no significant differences (p=0.81) (online supple-
mentary figure 1).
Clinical trials and outcomes
Distribution of primary tumour type in the PI3K-altered 
cohort of 30 patients who received PAMi was 11 (37%) 
ovarian, 10 (33%) endometrial and 9 (30%) cervical 
cancers (figure 1B). Most therapies (80%) were given 
at recommended doses as part of the expansion cohorts 
of phase I clinical trials (table 1). Table 2 details geno-
type-matched (PI3K-altered cohort that received PAMi) 
and unmatched trials (PI3K non-altered cohort that 
received PAMi) across tumour types. Most matched trials 
in patients with ovarian and cervical cancer consisted of 
single-agent PI3K-alpha inhibitors as opposed to patients 
with endometrial cancer who mostly enrolled on trials 
investigating pan-PI3K/mTOR (table 2).
The overall response rate (ORR) for the overall cohort 
was 10% (5 partial response; 0 complete response), 
without significant differences between patients enrolled 
on genotype-matched and genotype-unmatched clinical 
trials (13% vs 5%, respectively; p=1). Responses were 
observed across different tumour types, including rare 
histologies such as granulosa cell or clear cell ovarian 
cancers (online supplementary table 1).
No differences in ORR were found among patients 
treated with combinations of agents compared with 
patients treated with single agent therapies (p=1). The 
CBR was 40%; 37% in the genotype-matched cohort and 
39% in the unmatched cohort. Median TTP of PAMi-
treated patients was 3.57 months (95% CI 2.57 to 4.4 
months). The median TTP in patients with ovarian cancer 
was 4.2 months compared with 3.3 months in endometrial 
and 2.3 months in cervical cancer (HR ovarian vs others 
0.59; p=0.096; figure 2A). There was no significant associ-
ation between the presence of PI3K pathway gene muta-
tions and either CBR (OR 0.91, p=1 (0.2–3.7)) or median 
TTP (3.57 months (95% CI 2.6 to 4.4) vs 3.73 months 
(95% CI 1.9 to 13.2); HR 1.41; p=0.29) (figure 2B). Geno-
type-matched treatment did not improve median TTP 
among any tumour type (online supplementary figure 
2). Median TTP did not significantly differ according to 
PIK3CA codon mutation (exon 20: 4.40 months (95% CI 
4.17 to NA); exon 9: 2.63 months (95% CI 1.63 to 8.83); 
HR 1.71, p=0.24) (online supplementary figure 3). Due 
to the interest in the development of isotype-specific PI3K 
inhibitors, we investigated the efficacy of p110α inhibi-
tors. In the 26 patients treated with p110α inhibitors, no 
significant association was observed between CBR and 
PIK3CA mutational status (OR 0.36; p=0.56 (0.005–7.9)) 
(table 3).
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Median (range) 57 (30–70) 55 (30–70) 59 (34–68) 0.69
Subtype/histology
Ovarian 24 (48%) 11 (37%) 13 (65%) 0.12
  Serous papillary 9 1 8
  Clear cell 5 5 0
  Endometrioid 3 2 1
  Granulosa cell 3 2 1
  Mucinous 3 0 3
  Carcinosarcoma 1 1 0
Endometrial 15 (30%) 10 (33%) 5 (25%)
  Endometrioid 13 9 4
  Serous papillary 2 1 1
Cervical 11 (22%) 9 (30%) 2 (10%)
  Squamous 8 7 1
  Adenocarcinoma 3 2 1
Prior metastatic lines
Median (range) 2 (1–6) 2 (1–5) 2.5 (1–6) 0.69
≤2 29 (58%) 19 (63%) 10 (50%) 0.39
>2 21 (42%) 11 (37%) 10 (50%)
Molecular alterations
PIK3CA* 20 (40%) 20 (67%) 0 (0)
PTEN* 4 (8%) 4 (13%) 0 (0)
PIK3CA+PTEN† 2 (4%) 2 (7%) 0 (0)
PIK3CA+AKT1† 1 (2%) 1 (3%) 0 (0)
PIK3CA+KRAS/NRAS† 3 (6%) 3 (10%) 0 (0)
KRAS* 9 (18%) 0 (0) 9 (45%)
Trial dose
Escalation 10 (20%) 6 (20%) 4 (20%) 1
Expansion 40 (80%) 24 (80%) 16 (80%)
Trial best response
SD 28 (56%) 14 (47%) 14 (70%)
PD 14 (28%) 10 (33%) 4 (20%)
PR 5 (10%) 4 (13%) 1 (5%)
Unknown 3 (6%) 2 (7%) 1 (5%)
Trial reason for therapy discontinuation
Progression 33 (66%) 22 (73%) 11 (55%)
Toxicity 10 (20%) 3 (10%) 7 (35%)
Other 7 (14%) 5 (17%) 2 (10%)
*Alone.
†Co-mutation.
PD, progressive disease; PR, partial response; SD, stable disease.
Differences in TTP according to therapy were also 
assessed. We did not identify statistically significant differ-
ences in median TTP between PAMi combos, pan-PI3K/
mTOR/AKT inhibitors and PI3K-alpha inhibitors 
(2.57 months, 3.73 months and 3.57 months, respec-
tively; p=0.5) (online supplementary figure 4). We also 
Open access
5Rodriguez-Freixinos V, et al. ESMO Open 2019;4:e000444. doi:10.1136/esmoopen-2018-000444 Rodriguez-Freixinos V, et al. ESMO Open 2019;4:e000444. doi:10.1136/esmoopen-2018-000444
Figure 1 (A) Molecular alterations by primary tumour type. CC, cervical cancer; EC, endometrial cancer; mut, mutation; 
OC, ovarian cancer; WT, wild type for PIK3CA, AKT1, PTEN, KRAS, NRAS or HRAS mutations. *One of the patients also has 
NRAS mutation. (B) Distribution of PAMi treatments by primary tumour type. CC, cervical cancer; EC, endometrial cancer; OC: 
ovarian cancer; PAMi, PI3K/Akt/mTOR inhibitors; UM, genotype-unmatched.
investigated the potential impact of PIK3CA clonality on 
TTP with PAMi. Among patients with PIK3CA mutations, 
we found significant improvement of TTP with geno-
type-matched therapy in the presence of clonal events 
(4 months, 95% CI 3.5 to NA) compared with subclonal 
events (2.3 months, 95% CI 1.4 to NA; HR 3.6, p=0.03) 
(online supplementary figure 5).
Differences in TTP for genotype-matched and 
unmatched therapeutic trials compared with TTP on 
either the immediately prior or subsequent palliative 
chemotherapy (TTP PAMi:chemotherapy ratio) were 
also analysed in a total of 27 patients with available infor-
mation (online supplementary table 2). Overall, 41% of 
patients obtained a TTP PAMi:chemotherapy ratio ≥1.3, 
without statistically significant differences according 
to tumour type (p=0.39), molecular alteration status 
(p=0.13), treatment regimen (p=0.54) or PIK3CA clon-
ality (p=0.52) (figure 2C).
dIsCussIOn
Despite diversity in the molecular landscape and patterns 
of clinical outcomes across gynaecological malignancies, 
activation of the PI3K/AKT/mTOR pathway is common 
to these tumours, suggesting that PAMi may have thera-
peutic relevance. However, clinical trials evaluating PAMi 
in advanced gynaecological malignancies have shown 
a modest therapeutic impact.20 In addition, reliable 
biomarkers to guide patient selection for treatment with 
PAMi have yet to be identified. In our study, we demon-
strate that patients with advanced gynaecological cancer, 
refractory to standard therapies, achieved meaningful 
clinical benefit with PAMi, regardless of the presence or 
absence of mutations in the PI3K/AKT/mTOR pathway.
Although the precision medicine era in cancer therapy 
is rapidly evolving, the integration of comprehensive 
genomic profiling in routine clinical practice has been 
less robust in gynaecological malignancies than in other 
tumour types such as melanoma and non-small cell lung 
cancer in which successful biomarker-based selection of 
treatment has been widely documented.21–24 Nevertheless, 
over the past years, somatic tumour profiling has yielded 
important insights to tumour biology and has contrib-
uted to identify a wide variety of potentially targetable 
alterations, such as BRCA1/BRCA2 mutations in patients 
with high-grade serous ovarian cancer25 26 and potentially 
actionable PI3K/AKT/mTOR pathway alterations,27–33 
expanding therapeutic opportunities for patients with 
gynaecological cancer. To our knowledge, our study is 
one of the largest series reported to date of gynaecolog-
ical tumours that have been prospectively analysed with 
NGS through an institutional screening programme and 
treated with PAMi.34 35 We restricted targeted therapy 
to monotherapy or combinations with other targeted 
drugs, excluding combinations with chemotherapy in an 
attempt to avoid a confounding effect when studying the 
predictive value of PI3K pathway alterations for matched 
therapies. We were able to identify at least one somatic 
mutation in the majority (78%) of patients included in 
this cohort (PIK3CA in 52%, PTEN in 12% and AKT1 in 
2%), confirming the relevance of PI3K pathway alter-
ations in gynaecological malignancies and our enrich-
ment strategy in early clinical trials. This study provides 
valuable information regarding the impact of clinical and 
genomic heterogeneity on the efficacy of PAMi across 
multiple types of gynaecological tumours, including rare 
histologies such as clear cell, granulosa cell, mucinous or 
carcinosarcomas. We demonstrated a modest 10% ORR 
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PI3K alpha PI3Kalpha 8 (33%) 0 (0)
Pan PI3K/
mTOR or AKT
PI3KmTOR 1 (4%) 3 (13%)
PanPI3K 1 (4%) 0 (0)
mTOR 0 (0) 1 (4%)
AKT 0 (0) 2 (8%)
PAMi combos PanPI3K+MEK 0 (0) 4 (17%)
PI3Kalpha+MEK 0 (0) 2 (8%)
PI3Kalpha+IGF1R 1 (4%) 1 (4%)
Endometrial (N=15)
PI3K alpha PI3Kalpha 2 (13%) 0 (0)
Pan PI3K/
mTOR or AKT
PI3KmTOR 0 (0) 3 (20%)
PanPI3K 1 (7%) 0 (0)
mTOR 2 (13%) 0 (0)
PI3Kbeta 1 (7%) 0 (0)
PAMi combos PI3Kalpha+FGFR 1 (7%) 0 (0)
AKT+MEK 0 (0) 1 (7%)
PI3Kalpha+SYK 0 (0) 1 (7%)
PI3Kbeta+mTOR 1 (7%) 0 (0)
PI3Kalpha+mTOR 2 (13%) 0 (0)
Cervical (N=11)
PI3K alpha PI3Kalpha 7 (64%) 0 (0)
Pan PI3K/
mTOR or AKT
PI3KmTOR 1 (9%) 1 (9%)
PAMi combos panPI3K+MEK 0 (0) 1 (9%)
PI3Kalpha+mTOR 1 (9%) 0 (0)
PAMi, PI3K/AKT/mTOR inhibitors.
and median TTP of 3.27 months in the overall cohort. 
Despite a heavily pretreated population lacking approved 
therapeutic options, the observed 40% CBR is clinically 
noteworthy. Sixty per cent of patients were enrolled 
onto genotype-matched trials, mostly PI3Kalpha inhibi-
tors. However, none of the clinical outcomes that were 
assessed (ORR, TTP or CBR) were found to be associated 
with either the type of treatment (PAMi monotherapy vs 
combinations), tumour primary or PIK3CA mutational 
status. A key finding of our study is that 41% of patients 
achieved 30% increased TTP with PAMi compared 
with palliative chemotherapy given either immediately 
prior to or subsequently after experimental regimens, 
irrespective of their mutational status. Although a 
non-randomised comparison, this finding comprises an 
important and clinically meaningful metric in a cohort 
of patients with heavily pretreated gynaecological cancer 
with limited standard therapeutic options. Other studies 
found modest activity with single-agent mTOR inhibitors 
treatment, even in the setting of PI3K pathway activa-
tion, via mutation or amplification.36–44 Single-agent PI3K 
inhibitors also failed to demonstrate meaningful impact 
on gynaecological malignancies and again, PIK3CA 
mutational status did not correlate with responses.45–51 
The PIK3CA mutant variant may also impact response 
to PAMi,52 with PIK3CA H1047R mutations, which occur 
within the highly conserved kinase domain (exon 20), 
associated to increased likelihood of response to PAMi 
compared with other pathway aberrations.52
Comprehensive NGS testing may increase the number 
of patients with gynaecological cancer who are eligible for 
clinical trials assessing PAMi-based combinations. Several 
academic centres have demonstrated that targeted NGS 
can be used in routine clinical practice. However, despite 
the elevated proportion (75%–90%) of potentially action-
able alterations detected, genomic profiling data are used 
as criteria for selection of a targeted therapy or clinical 
trial in only 5%–10% of cases.34 35 53–62 Some reports have 
focused on the experience of PAMi among a cohort of 
patients with gynaecological cancer enrolled onto early 
phase I clinical trials. In a retrospective analysis of 140 
patients with breast and gynaecological cancer treated 
with PAMi at the MD Anderson Cancer Center, a higher 
response rate to PAMi was observed in PIK3CA-mutated 
versus PIK3CA-wild-type tumours5 and the majority of 
responses were seen in patients receiving combination 
therapies with PAMi and cytotoxic drugs. Another study 
in 55 patients with cervical cancer demonstrated that 
genotype-matched therapy with PAMi led to a favourable 
CBR at 6 months (53%) and significantly greater progres-
sion-free survival (PFS) than non-matched therapies.35 
Limited activity of single-agent PAMi, particularly mTOR 
inhibitors, has been reported in patients with tumours 
harbouring KRAS mutations.63–65 In our study, of the 
four patients with KRAS mutations who were treated with 
single-agent PAMi, none derived clinical benefit. Addi-
tionally, we explored the impact of clonality of PIK3CA 
mutations on PAMi efficacy. PIK3CA clonal events, 
defined by adjMAF >0.4, were identified in 62% (100%–
38%) of tumours, with a higher proportion in ovarian 
cancer. In univariate analysis, we found an association 
between clonal PIK3CA events and improved outcomes 
under PI3K inhibitors. Clonality of AKT E17K muta-
tions in solid tumours, including gynaecological cancers, 
frequently exhibited selection against the remaining 
wild-type allele, by duplication of the mutant AKT1 allele 
via copy-neutral loss of heterozygosity. Interestingly, this 
AKT1 E17K allelic imbalance was shown to influence the 
response to AZD5363 (AKT inhibitor) (median PFS, 8.2 
vs 4.1 months, respectively; HR 0.41; p=0.04).66 Contra-
dictory, clonality of PIK3CA mutations did not predict 
benefit with matched targeted agents in patients with 
colorectal cancer.10 These results were partially explained 
by the limited activity in the PIK3CA/KRAS co-mutant 
populations,10 known to confer primary resistance to 
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Figure 2 (A) Trial time to progression (TTP) by tumour type. (B) Trial TTP by genotype-matched therapy (N=50). (C) 
Differences in TTP for therapeutic trials compared with immediate prior (*) or posterior palliative chemotherapy. Patients 
achieving TTP PAMi:palliative chemotherapy ratio ≥1.3 are coloured in dark blue. Primary tumour site of patients achieving 
TTP >4 months with PAMi is shown. M, genotype-matched clinical trials; PI3K alpha, PI3K alpha inhibitor; PAMi, PI3K/Akt/
mTOR inhibitors; pan PI3K/mTOR/AKT, PI3K/mTOR/AKT inhibitors.
Table 3 Clinical benefit obtained with PAMi
Clinical benefit
OR (95% CI) P valueNo Yes
PI3K pathway alterations
(N=50)
No 11 (61%) 7 (39%) 0.91 (0.2 to 3.7) 1
Yes 19 (63%) 11 (37%)
PIK3CA status
(N=50)
Wt 15 (68%) 7 (32%) 1.56 (0.4 to 6.2) 0.5
Mut 15 (58%) 11 (42%)
Patients treated with PI3Kalpha inhibitors, 
according to PIK3CA status (N=26)*
Wt† 1 (33%) 2 (67%) 0.36 (0.005 to 7.9) 0.56
Mut 13 (59%) 9 (41%)
*One PIK3CA wild-type patient not assessed for clinical benefit.
†Patients treated with PI3K alpha inhibitor in either monotherapy or combination.
Mut, mutation; Wt, wild type.
PAMi as single agents.67–71 The association between MAFs 
of driver genes identified through circulating tumour 
DNA (ctDNA) NGS and clinical outcomes with targeted 
therapy may potentially yield findings with broad impli-
cations. A recent report has evidenced clinical responses 
in patients with undetectable AKT1 E17K in pretreat-
ment ctDNA, which suggests that low tumour burden can 
negatively impact genomic screening strategies that rely 
on this technology for patient selection; however, serial 
ctDNA monitoring for AKT1 mutations might be used 
as a surrogate marker of treatment response or disease 
progression.66
The identification of reliable biomarkers to guide appro-
priate patient selection for PAMi remains a significant chal-
lenge. Multiple mechanisms, not necessarily related to the 
intrinsic activation status of the PI3K pathway, have been 
attributed to the modest activity of PAMi demonstrated 
across a variety of solid tumours, including intrapathway 
or interpathway cross-talks or alternate signalling cascades, 
such as activation of the MAPK pathway following treatment 
with PAMi.67–71 Despite existing barriers that limit access to 
genotype-matched therapies and clinical trials for gynae-
cological cancers, and the complexity of PI3K pathway 
inhibition, our data suggest promising activity of PAMi 
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in patients with heavily pretreated gynaecological cancer, 
regardless of the presence of mutations in the pathway. 
Despite the small sample size and the lack of adjustment 
for copy-number analysis when estimating mutation clon-
ality, PIK3CA clonal mutations may be important to guide 
the selection of targeted therapy in patients with advanced 
gynaecological cancer. This may become even more rele-
vant when the dynamics of clonal evolution is taken into 
consideration, with consecutive liquid biopsies to assess 
mutation clonality. Furthermore, intratumoural heteroge-
neity has been proposed as the main cause of treatment 
failure and drug resistance in ovarian cancer and other 
primary cancer,72 and we noted that in our study, 80% 
of analyses were performed in primary tumour samples 
raising the question whether tumour evolution and 
the degree of intratumoural heterogeneity might have 
impacted on our results. However, difficulties in collection 
of longitudinal samples from patients with cancer and the 
high costs of genomic profiling must be recognised. Addi-
tional correlative analyses from ongoing studies with PAMi 
and improved access to biomarker-matched (‘basket’) clin-
ical trials are required to help elucidate the role of PAMi 
in gynaecological cancer and improve patient selection for 
these targeted therapies.
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